New Delhi: US-based drug maker Pfizer has told the central government that its Covid vaccine shows “high effectiveness” against variants of coronaviruses in India. Experts believe that this is the variant behind the devastating second wave of infection and deaths in the country.
Sources said that Pfizer also told the central government that its vaccine has proved to be suitable for everyone above 12 years of age. The important thing is that it can be safely stored for up to a month in cold storage facilities between two to eight degree Celsius temperature range.
The US pharma giant has requested the central government to grant fast-track clearance for the use of this vaccine and said that between July and October, five crore doses will roll out if the government receives compensation, or compensation in case of adverse events. Gives significant regulatory exemption, including protection from claims of. However, none of the three vaccines (Covishield, Covaxin and Sputnik V) being used in the country have been given the same exemption as the rebate Pfizer is seeking.
Read also: Cong pays tributes to Nehru on death anniversary
Pfizer has asked Indian authorities for early approval of her Covid-19 vaccine in India, saying that her vaccine is highly effective against the corona variant spread in India and that it can be applied to children over the age of 12. . Pfizer has said that its vaccine has shown to be very effective against the SARS-COV-2 variant spread in India and on the Indian people.
